Geron Announces First Patient Dosed In Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat In Patients With Relapsed/Refractory AML Or Higher Risk MDS
Portfolio Pulse from Benzinga Newsdesk
Geron announced the first patient dosed in an investigator-led Phase 2 IMpress trial evaluating imetelstat in patients with relapsed/refractory acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (MDS). Pre-clinical data showed imetelstat prevented expansion of human AML leukemic stem cells and prolonged survival of mice.
June 13, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geron's Phase 2 IMpress trial for imetelstat in patients with relapsed/refractory AML and higher risk MDS has begun, with promising pre-clinical data.
The initiation of the Phase 2 IMpress trial for imetelstat is a significant milestone for Geron. The promising pre-clinical data indicates potential for the drug's success in treating relapsed/refractory AML and higher risk MDS patients. This development could positively impact Geron's stock price in the short term as investors may see it as a sign of progress and potential future revenue.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100